James D. Stewart
University of North Carolina at Chapel Hill
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by James D. Stewart.
Annals of Epidemiology | 2008
Janne E. Boone; Penny Gordon-Larsen; James D. Stewart; Barry M. Popkin
PURPOSE To validate a commercial database of community-level physical activity facilities that can be used in future research examining associations between access to physical activity facilities and individual-level physical activity and obesity. METHODS Physical activity facility characteristics and locations obtained from a commercial database were compared to a field census conducted in 80 census block groups within two U.S. communities. Agreement statistics, agreement of administratively defined neighborhoods, and distance between locations were used to quantify count, attribute, and positional error. RESULTS There was moderate agreement (concordance: nonurban: 0.39; urban: 0.46) of presence of any physical activity facility and poor to moderate agreement (kappa range: 0.14 to 0.76) of physical activity facility type. The mean Euclidean distance between commercial database versus field census locations was 757 and 35 m in the nonurban and urban communities, respectively. However, 94% and 100% of nonurban and urban physical activity facilities, respectively, fell into the same 5-digit ZIP code, dropping to 92% and 98% in the same block group and 71% along the same street. CONCLUSIONS Our findings suggest that the commercial database of physical activity facilities may contain appreciable error, but patterns of error suggest that built environment-health associations are likely biased downward.
Aging | 2017
Austin Quach; Morgan E. Levine; Toshiko Tanaka; Ake T. Lu; Brian H. Chen; Luigi Ferrucci; Beate Ritz; Stefania Bandinelli; Marian L. Neuhouser; Jeannette M. Beasley; Linda Snetselaar; Robert B. Wallace; Philip S. Tsao; Devin Absher; Themistocles L. Assimes; James D. Stewart; Yun Li; Lifang Hou; Andrea Baccarelli; Eric A. Whitsel; Steve Horvath
Behavioral and lifestyle factors have been shown to relate to a number of health-related outcomes, yet there is a need for studies that examine their relationship to molecular aging rates. Toward this end, we use recent epigenetic biomarkers of age that have previously been shown to predict all-cause mortality, chronic conditions and age-related functional decline. We analyze cross-sectional data from 4,173 postmenopausal female participants from the Womens Health Initiative, as well as 402 male and female participants from the Italian cohort study, Invecchiare nel Chianti. Extrinsic epigenetic age acceleration (EEAA) exhibits significant associations with fish intake (p=0.02), moderate alcohol consumption (p=0.01), education (p=3×10-5), BMI (p=0.01), and blood carotenoid levels (p=1×10-5)—an indicator of fruit and vegetable consumption, whereas intrinsic epigenetic age acceleration (IEAA) is associated with poultry intake (p=0.03) and BMI (p=0.05). Both EEAA and IEAA were also found to relate to indicators of metabolic syndrome, which appear to mediate their associations with BMI. Metformin—the first-line medication for the treatment of type 2 diabetes—does not delay epigenetic aging in this observational study. Finally, longitudinal data suggests that an increase in BMI is associated with increase in both EEAA and IEAA. Overall, the epigenetic age analysis of blood confirms the conventional wisdom regarding the benefits of eating a high plant diet with lean meats, moderate alcohol consumption, physical activity, and education, as well as the health risks of obesity and metabolic syndrome.
bioRxiv | 2018
Morgan E. Levine; Ake T. Lu; Austin Quach; Brian H. Chen; Themistocles L. Assimes; Stefania Bandinelli; Lifang Hou; Andrea Baccarelli; James D. Stewart; Yun Li; Eric A. Whitsel; James G. Wilson; Alex P. Reiner; Abraham Aviv; Kurt Lohman; Yongmei Liu; Luigi Ferrucci; Steve Horvath
Identifying reliable biomarkers of aging is a major goal in geroscience. While the first generation of epigenetic biomarkers of aging were developed using chronological age as a surrogate for biological age, we hypothesized that incorporation of composite clinical measures of phenotypic age that capture differences in lifespan and healthspan may identify novel CpGs and facilitate the development of a more powerful epigenetic biomarker of aging. Using an innovative two-step process, we develop a new epigenetic biomarker of aging, DNAm PhenoAge, that strongly outperforms previous measures in regards to predictions for a variety of aging outcomes, including all-cause mortality, cancers, healthspan, physical functioning, and Alzheimers disease. While this biomarker was developed using data from whole blood, it correlates strongly with age in every tissue and cell tested. Based on an in-depth transcriptional analysis in sorted cells, we find that increased epigenetic, relative to chronological age, is associated with increased activation of pro-inflammatory and interferon pathways, and decreased activation of transcriptional/translational machinery, DNA damage response, and mitochondrial signatures. Overall, this single epigenetic biomarker of aging is able to capture risks for an array of diverse outcomes across multiple tissues and cells, and provide insight into important pathways in aging.
Environment International | 2017
Trenton Honda; Melissa N. Eliot; Charles B. Eaton; Eric A. Whitsel; James D. Stewart; Lina Mu; Helen Suh; Adam A. Szpiro; Joel D. Kaufman; Sverre Vedal; Gregory A. Wellenius
BACKGROUND Long-term exposure to ambient particulate matter (PM) has been previously linked with higher risk of cardiovascular events. This association may be mediated, at least partly, by increasing the risk of incident hypertension, a key determinant of cardiovascular risk. However, whether long-term exposure to PM is associated with incident hypertension remains unclear. METHODS Using national geostatistical models incorporating geographic covariates and spatial smoothing, we estimated annual average concentrations of residential fine (PM2.5), respirable (PM10), and course (PM10-2.5) fractions of particulate matter among 44,255 post-menopausal women free of hypertension enrolled in the Womens Health Initiative (WHI) clinical trials. We used time-varying Cox proportional hazards models to evaluate the association between long-term average residential pollutant concentrations and incident hypertension, adjusting for potential confounding by sociodemographic factors, medical history, neighborhood socioeconomic measures, WHI study clinical site, clinical trial, and randomization arm. RESULTS During 298,383 person-years of follow-up, 14,511 participants developed incident hypertension. The adjusted hazard ratios per interquartile range (IQR) increase in PM2.5, PM10, and PM10-2.5 were 1.13 (95% CI: 1.08, 1.17), 1.06 (1.03, 1.10), and 1.01 (95% CI: 0.97, 1.04), respectively. Statistically significant concentration-response relationships were identified for PM2.5 and PM10 fractions. The association between PM2.5 and hypertension was more pronounced among non-white participants and those residing in the Northeastern United States. CONCLUSIONS In this cohort of post-menopausal women, ambient fine and respirable particulate matter exposures were associated with higher incidence rates of hypertension. These results suggest that particulate matter may be an important modifiable risk factor for hypertension.
Circulation-cardiovascular Genetics | 2017
Shia T. Kent; Robert S. Rosenson; Christy L. Avery; Yii-Der Ida Chen; Adolfo Correa; Steven R. Cummings; L. Adrienne Cupples; Mary Cushman; Daniel S. Evans; Vilmundur Gudnason; Tamara B. Harris; George Howard; Marguerite R. Irvin; Suzanne E. Judd; J. Wouter Jukema; Leslie A. Lange; Emily B. Levitan; Xiaohui Li; Yongmei Liu; Wendy S. Post; Iris Postmus; Bruce M. Psaty; Jerome I. Rotter; Monika M. Safford; Colleen M. Sitlani; Albert V. Smith; James D. Stewart; Stella Trompet; Fangui Sun; J. Michael Woolley
Background— PCSK9 loss-of-function (LOF) variants allow for the examination of the effects of lifetime reduced low-density lipoprotein cholesterol (LDL-C) on cardiovascular events. We examined the association of PCSK9 LOF variants with LDL-C and incident coronary heart disease and stroke through a meta-analysis of data from 8 observational cohorts and 1 randomized trial of statin therapy. Methods and Results— These 9 studies together included 17 459 blacks with 403 (2.3%) having at least 1 Y142X or C679X variant and 31 306 whites with 955 (3.1%) having at least 1 R46L variant. Unadjusted odds ratios for associations between PCSK9 LOF variants and incident coronary heart disease (851 events in blacks and 2662 events in whites) and stroke (523 events in blacks and 1660 events in whites) were calculated using pooled Mantel–Haenszel estimates with continuity correction factors. Pooling results across studies using fixed-effects inverse-variance-weighted models, PCSK9 LOF variants were associated with 35 mg/dL (95% confidence interval [CI], 32–39) lower LDL-C in blacks and 13 mg/dL (95% CI, 11–16) lower LDL-C in whites. PCSK9 LOF variants were associated with a pooled odds ratio for coronary heart disease of 0.51 (95% CI, 0.28–0.92) in blacks and 0.82 (95% CI, 0.63–1.06) in whites. PCSK9 LOF variants were not associated with incident stroke (odds ratio, 0.84; 95% CI, 0.48–1.47 in blacks and odds ratio, 1.06; 95% CI, 0.80–1.41 in whites). Conclusions— PCSK9 LOF variants were associated with lower LDL-C and coronary heart disease incidence. PCSK9 LOF variants were not associated with stroke risk.
Journal of Medical Genetics | 2017
Raymond Noordam; Colleen M. Sitlani; Christy L. Avery; James D. Stewart; Stephanie M. Gogarten; Kerri L. Wiggins; Stella Trompet; Helen R. Warren; Fangui Sun; Daniel S. Evans; Xiaohui Li; Jin Li; Albert V. Smith; Joshua C. Bis; Jennifer A. Brody; Evan L. Busch; Mark J. Caulfield; Yii-Der I. Chen; Steven R. Cummings; L. Adrienne Cupples; Qing Duan; Oscar H. Franco; Raúl Méndez-Giráldez; Tamara B. Harris; Susan R. Heckbert; Diana van Heemst; Albert Hofman; James S. Floyd; Jan A. Kors; Lenore J. Launer
Background Increased heart rate and a prolonged QT interval are important risk factors for cardiovascular morbidity and mortality, and can be influenced by the use of various medications, including tricyclic/tetracyclic antidepressants (TCAs). We aim to identify genetic loci that modify the association between TCA use and RR and QT intervals. Methods and results We conducted race/ethnic-specific genome-wide interaction analyses (with HapMap phase II imputed reference panel imputation) of TCAs and resting RR and QT intervals in cohorts of European (n=45 706; n=1417 TCA users), African (n=10 235; n=296 TCA users) and Hispanic/Latino (n=13 808; n=147 TCA users) ancestry, adjusted for clinical covariates. Among the populations of European ancestry, two genome-wide significant loci were identified for RR interval: rs6737205 in BRE (β=56.3, pinteraction=3.9e−9) and rs9830388 in UBE2E2 (β=25.2, pinteraction=1.7e−8). In Hispanic/Latino cohorts, rs2291477 in TGFBR3 significantly modified the association between TCAs and QT intervals (β=9.3, pinteraction=2.55e−8). In the meta-analyses of the other ethnicities, these loci either were excluded from the meta-analyses (as part of quality control), or their effects did not reach the level of nominal statistical significance (pinteraction>0.05). No new variants were identified in these ethnicities. No additional loci were identified after inverse-variance-weighted meta-analysis of the three ancestries. Conclusions Among Europeans, TCA interactions with variants in BRE and UBE2E2 were identified in relation to RR intervals. Among Hispanic/Latinos, variants in TGFBR3 modified the relation between TCAs and QT intervals. Future studies are required to confirm our results.
Pharmacogenomics Journal | 2018
James S. Floyd; Colleen M. Sitlani; Christy L. Avery; Raymond Noordam; Xiaohui Li; Albert V. Smith; Stephanie M. Gogarten; Jun Li; Linda Broer; Daniel S. Evans; Stella Trompet; Jennifer A. Brody; James D. Stewart; John D. Eicher; A A Seyerle; Jeffrey Roach; Leslie A. Lange; Henry J. Lin; Jan A. Kors; T. B. Harris; Ruifang Li-Gao; Naveed Sattar; Steven R. Cummings; Kerri L. Wiggins; Melanie D. Napier; Til Stürmer; J. C. Bis; Kathleen F. Kerr; A.G. Uitterlinden; Kent D. Taylor
Sulfonylureas, a commonly used class of medication used to treat type 2 diabetes, have been associated with an increased risk of cardiovascular disease. Their effects on QT interval duration and related electrocardiographic phenotypes are potential mechanisms for this adverse effect. In 11 ethnically diverse cohorts that included 71 857 European, African-American and Hispanic/Latino ancestry individuals with repeated measures of medication use and electrocardiogram (ECG) measurements, we conducted a pharmacogenomic genome-wide association study of sulfonylurea use and three ECG phenotypes: QT, JT and QRS intervals. In ancestry-specific meta-analyses, eight novel pharmacogenomic loci met the threshold for genome-wide significance (P<5 × 10−8), and a pharmacokinetic variant in CYP2C9 (rs1057910) that has been associated with sulfonylurea-related treatment effects and other adverse drug reactions in previous studies was replicated. Additional research is needed to replicate the novel findings and to understand their biological basis.
Aging | 2018
Steve Horvath; Junko Oshima; George M. Martin; Ake T. Lu; Austin Quach; Howard Cohen; Sarah Felton; Mieko Matsuyama; Donna Lowe; Sylwia Kabacik; James G. Wilson; Alex P. Reiner; Anna Maierhofer; Julia Flunkert; Abraham Aviv; Lifang Hou; Andrea Baccarelli; Yun Li; James D. Stewart; Eric A. Whitsel; Luigi Ferrucci; Shigemi Matsuyama; Kenneth Raj
DNA methylation (DNAm)-based biomarkers of aging have been developed for many tissues and organs. However, these biomarkers have sub-optimal accuracy in fibroblasts and other cell types used in ex vivo studies. To address this challenge, we developed a novel and highly robust DNAm age estimator (based on 391 CpGs) for human fibroblasts, keratinocytes, buccal cells, endothelial cells, lymphoblastoid cells, skin, blood, and saliva samples. High age correlations can also be observed in sorted neurons, glia, brain, liver, and even bone samples. Gestational age correlates with DNAm age in cord blood. When used on fibroblasts from Hutchinson Gilford Progeria Syndrome patients, this age estimator (referred to as the skin & blood clock) uncovered an epigenetic age acceleration with a magnitude that is below the sensitivity levels of other DNAm-based biomarkers. Furthermore, this highly sensitive age estimator accurately tracked the dynamic aging of cells cultured ex vivo and revealed that their proliferation is accompanied by a steady increase in epigenetic age. The skin & blood clock predicts lifespan and it relates to many age-related conditions. Overall, this biomarker is expected to become useful for forensic applications (e.g. blood or buccal swabs) and for a quantitative ex vivo human cell aging assay.
Environmental Health Perspectives | 2018
Melinda C. Power; Archana P. Lamichhane; Duanping Liao; Xiaohui Xu; Clifford R. Jack; Rebecca F. Gottesman; Thomas H. Mosley; James D. Stewart; Jeff D. Yanosky; Eric A. Whitsel
Background: Increasing evidence links higher particulate matter (PM) air pollution exposure to late-life cognitive impairment. However, few studies have considered associations between direct estimates of long-term past exposures and brain MRI findings indicative of neurodegeneration or cerebrovascular disease. Objective: Our objective was to quantify the association between brain MRI findings and PM exposures approximately 5 to 20 y prior to MRI in the Atherosclerosis Risk in Communities (ARIC) study. Methods: ARIC is based in four U.S. sites: Washington County, Maryland; Minneapolis suburbs, Minnesota; Forsyth County, North Carolina; and Jackson, Mississippi. A subset of ARIC participants underwent 3T brain MRI in 2011–2013 (n=1,753). We estimated mean exposures to PM with an aerodynamic diameter less than 10 or 2.5μm (PM10 and PM2.5) in 1990–1998, 1999–2007, and 1990–2007 at the residential addresses of eligible participants with MRI data. We estimated site-specific associations between PM and brain MRI findings and used random-effect, inverse variance–weighted meta-analysis to combine them. Results: In pooled analyses, higher mean PM2.5 and PM10 exposure in all time periods were associated with smaller deep-gray brain volumes, but not other MRI markers. Higher PM2.5 exposures were consistently associated with smaller total and regional brain volumes in Minnesota, but not elsewhere. Conclusions: Long-term past PM exposure in was not associated with markers of cerebrovascular disease. Higher long-term past PM exposures were associated with smaller deep-gray volumes overall, and higher PM2.5 exposures were associated with smaller brain volumes in the Minnesota site. Further work is needed to understand the sources of heterogeneity across sites. https://doi.org/10.1289/EHP2152
Pharmacogenomics Journal | 2017
Amanda A. Seyerle; Colleen M. Sitlani; Raymond Noordam; Stephanie M. Gogarten; J. Li; Xin Li; Daniel S. Evans; Fangui Sun; Maarit A. Laaksonen; Aaron Isaacs; Kati Kristiansson; Heather M. Highland; James D. Stewart; T. B. Harris; S. Trompet; J. C. Bis; Gina M. Peloso; Jennifer A. Brody; Linda Broer; Evan L. Busch; Qing Duan; A. M. Stilp; Christoper J. O'Donnell; Peter W. Macfarlane; James S. Floyd; Jan A. Kors; Henry J. Lin; Ruifang Li-Gao; Tamar Sofer; Raúl Méndez-Giráldez
Thiazide diuretics, commonly used antihypertensives, may cause QT interval (QT) prolongation, a risk factor for highly fatal and difficult to predict ventricular arrhythmias. We examined whether common single-nucleotide polymorphisms (SNPs) modified the association between thiazide use and QT or its component parts (QRS interval, JT interval) by performing ancestry-specific, trans-ethnic and cross-phenotype genome-wide analyses of European (66%), African American (15%) and Hispanic (19%) populations (N=78 199), leveraging longitudinal data, incorporating corrected standard errors to account for underestimation of interaction estimate variances and evaluating evidence for pathway enrichment. Although no loci achieved genome-wide significance (P<5 × 10−8), we found suggestive evidence (P<5 × 10−6) for SNPs modifying the thiazide-QT association at 22 loci, including ion transport loci (for example, NELL1, KCNQ3). The biologic plausibility of our suggestive results and simulations demonstrating modest power to detect interaction effects at genome-wide significant levels indicate that larger studies and innovative statistical methods are warranted in future efforts evaluating thiazide–SNP interactions.